Core Insights - The drug discovery process is inefficient, requiring an average of 2,500 compounds and over four years to find one candidate for clinical trials [2][4] - Artificial intelligence (AI) is transforming drug discovery by analyzing large datasets and speeding up the identification of promising compounds [3] Company Summaries Recursion Pharmaceuticals - Recursion Pharmaceuticals has improved the drug discovery process, averaging 330 compounds synthesized in 17 months compared to the industry average [4] - The company utilizes a drug development operating system that integrates robotic labs, large biological datasets, and AI models, with proprietary datasets valued at $213 million from Roche and Genentech [5] - For full-year 2025, Recursion's revenue is projected at $74.7 million, with five clinical programs in progress and a cash runway extending into 2028 [6] - The company has demonstrated clinical proof-of-concept with a 43% median reduction in polyp burden for Familial Adenomatous Polyposis patients [6] Tempus AI - Tempus AI has developed a vast library of clinical and molecular data to enhance precision medicine, focusing on oncology, diagnostics, and genomics [8] - The company reported trailing revenue of $1.27 billion, growing approximately 30% annually, with a strong data engine driven by diagnostics [9] - Tempus is currently unprofitable with a net loss of $245 million, but analysts project nearly 30% annual revenue growth over the next three years [12] Industry Context - The healthcare industry in the U.S. is valued at $4.7 trillion, and advancements in AI could significantly change drug discovery and disease diagnosis [13] - Both Recursion Pharmaceuticals and Tempus AI are positioned to become integral parts of the evolving healthcare infrastructure [13][14]

Core Thesis - Tempus AI, Inc. (TEM) is positioned as a long-term growth opportunity at the intersection of oncology, data compounding, and artificial intelligence, with a focus on building the largest library of clinical and molecular data [2][4]. Business Model and Data Flywheel - The company is creating a powerful data flywheel where increased usage by oncologists enhances the database, leading to improved AI-driven insights that attract pharmaceutical companies for drug discovery [3][4]. - Tempus' model is designed for decades of intrinsic value growth, with applications in pathology and cardiology expected to transition from experimental to industry standard, establishing the company as a generational asset in healthcare AI [4]. Investment Strategy - A strategic approach involves selling 1,500 January 2027 $50 put contracts at $8.35, setting a target entry price of $41.65, which offers a significant margin of safety compared to current valuations [3][5]. - This disciplined method allows for capturing long-term upside while mitigating short-term volatility, ensuring ownership occurs at an attractive risk-reward point [5][6]. Financial Performance and Projections - Previous analyses indicated strong revenue and EBITDA growth projections of over 20% over two years, with an attractive valuation at 6x NTM sales [7]. - Since the last coverage, TEM's stock price has appreciated by 18.89%, reflecting positive market sentiment [7].